Wockhardt shares hit 5% upper circuit after Prashant Jain, Madhusudan Kela and others invest in QIP

3P India Equity Fund, managed by Prashant Jain, and Madhusudan Kela's Cohesion MK Best Ideas sub-trust are among those funds that have received 5% or more shares in the Qualified Institutional Placement (QIP) of shares.

Shares of hit an upper circuit of 5% at Rs 555.8 in Wednesday trade after the company said it raised Rs 480 crore via Qualified Institutional Placement (QIP) of shares.

Funds owned/managed by veteran investors and are part of the institutions that have invested in the QIP of Wockhardt, according to an exchange filing.

The drug manufacturer's capital raising committee approved and determined the allocation of 92.85 lakh shares at an issue price of Rs 517 per share, which includes a discount of Rs 27.02, or 4.97%, to the floor price of Rs 544.02 per share.

3P India Equity Fund, managed by Prashant Jain, and Madhusudan Kela's Cohesion MK Best Ideas sub-trust are among those funds that have received 5% or more shares in the QIP.

Also, ICICI Prudential, Mirae Asset Management, Tata Indian Opportunities Fund, Invesco India Small Cap Fund, Gagandeep Credit Capital, and Subhkam Ventures are some of the other funds that have been issued shares within the QIP.

The QIP of shares was open from March 20 to March 26.

After the QIP, the paid-up equity share capital of will increase to Rs 76.7 crore, comprising 15.34 crore equity shares of face value of Rs 5 each from Rs 72.05 crore consisting of Rs 14.41 crore shares of face value of Rs 5 each.

Technically, the stock's day RSI (14) is at 47.9. The RSI below 30 is considered oversold and above 70 is overbought, Trendlyne data showed. MACD is at 10.7, which is above its center line, but below the signal line. Wockhardt stock stood higher than the 5-day, 10-day, 30-day, 50-day, 100-day, 150-day and 200-day moving averages.

Wockhardt is engaged in manufacturing and marketing pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs), and vaccines. The company is a small-cap pharma firm commanding a market cap of Rs 8,009 crore. Its PE currently stands at -13.23.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)


Source: Stocks-Markets-Economic Times

Останні публікації
Oklo target nearly doubled at Wedbush on AI-driven demand for nuclear energy
24.01.2025 - 18:00
Crypto markets lose steam after Trump's first policy move
24.01.2025 - 18:00
Combination of Google's TPU-DeepMind units may be worth $700 bn - DA Davidson
24.01.2025 - 18:00
British American Tobacco, Altria shares rise after menthol ban proposal dropped
24.01.2025 - 18:00
Morocco stocks higher at close of trade; Moroccan All Shares up 0.34%
24.01.2025 - 18:00
Commerzbank says no talks with UniCredit until specific proposal made
24.01.2025 - 18:00
Venture Global aims for $64 billion valuation at debut in test for energy IPOs
24.01.2025 - 18:00
Intuitive Machines stock surges on NASA contract award
24.01.2025 - 18:00
International Paper's $7.2 billion acquisition of DS Smith gets EU approval
24.01.2025 - 18:00
Short-term stock optimism soars among retail investors, AAII survey shows
24.01.2025 - 18:00
Venture Global shares likely to open up to 6% above IPO price
24.01.2025 - 18:00
Intuitive Surgical, American Express Stir Friday's Market Cap Stock Movers
24.01.2025 - 18:00
BMW joins Chinese EV makers in filing EU court challenge to tariffs
24.01.2025 - 18:00
Turkey stocks lower at close of trade; BIST 100 down 0.08%
24.01.2025 - 18:00
Diageo stock jumps on possible Guinness sale
24.01.2025 - 18:00

© Analytic DC. All Rights Reserved.